CYBIN INC.

HELP

Held by 5 specialist biotech funds

High Convergence

5 funds opened new positions. Next phase3 readout (CYB003): Aug 2026.

BiotechnologyCEO: Michael F. ColaIPO: 2019Website ↗

Clinical-stage biopharmaceutical company developing psychedelic-based therapeutics including CYB003 (deuterated psilocybin analog) for major depressive disorder and CYB004 (deuterated DMT) for generalized anxiety disorder

CYBIN INC.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Activist Filings

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research